<prompt> Which of the following drugs is not used for the management of multiple myelomaBoezomibHydroxyureaMelphelanCyclophosphamide  <response>: Answer is B Hydroxyurea Hydroxyurea is not recommended for the management of multiple myeloma Chemotherapeutic Agents Recommended in the management of multiple myeloma Boezomib Cyclophosphamide Doxorubicin Vincristine Lenalidomide Thalidomide Melphelan Dexamethasone Prednisolone Interferon Maintenance The most commonly used chemotherapy agents in non-transplant and transplant candidates and in relapsed orrefractory myeloma, based on the 2007 National Comprehensive Cancer Network NCCN guidelines Primary Induction therapy for transplant candidates Primary Induction Therapy for non-transplant Candidates Boezomibdexamethasone category 1 Boezomibdexamethasone Boezomibcyclophosphamidedexamethasone Dexamethasone category 2B Bonezomibdoxorubicindexamethasone category I Lenalidomidelow-dose dexamethasone category 1 BoezomibenalidomideQdexamethasone category 2B Liposomal doxorubicinvincristinedexamethasone D VD Boezomibthalidomidedexamethasone category 1 category 2B Dexamethasone category 2B Melphalanprednisone MP Lenalidomidedexamethasone category I Melphalanprednisoneboezomib MPB category I Liposomal doxorubicinvincristinedexamethasone Melphalanprednisonethalidomide MPT category 1 DVD category 2B Melphalanprednisonelenalidomide MPL Thalidomidedexamethasone category 2B Thalidomidedexamethasone category 2B Vincristinedoxorubicindexamethasone VAD cateoory 2B Maintenance Therapy Sal Interferon category 2B Repeat primary induction therapy if relapse at 6 mo Lenalidomide Bendamustine category 2B Steroids category 2B Boezomibg category 1 Thalidomide category 1 -prednisone category 2B Boezomibdexamethasone Borlezomiblenalidomidedexamethasone category 2B Boezomibliposomal doxorubicing category I Cyclophosphamide-VAD Cyclophosphamideboezomibdexamethasoneh Cyclophosphamidelenalidomidedexamethasoneh Dexamethasone Dexamethasonecyclophasphamideetoposidecisplatin DCEP Dexamethasonethalidomidecisplatindoxorubicin cyclophosphamideetoposide DT-PACE High-dose cyclophosphamide Lenalidomidedexamethasone category 1 Lenalidomide Thalidomide Thalidomidedexamethasone aSelected, but not inclusive of all regimens --Thalidomidedexamethasone bTreatments are listed alphabatically and do not imply preference. cRecommend herpes zoster prophylaxis for patients treated with boezomib dProphylactic anticoagulation recommended for patients receiving thalidomide-based therapy or lenalidomide with dexmethasone. fLenalidomide as maintenance has been evaluated in three independent randomized clinical trials. Results from each of these trials show improvements in TTP. The panel felt that this warranted inclusion: however, this recommendation remains Category 2A since these results have not undergone full peer review and safetyefficacy data are still preliminary. gBoezomibliposomal doxorubicin is prefered to boezumib single agent hThese are representative regimens combining standard agents with novel agents Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Paicipation in clinical tirals is especially encouraged. 